News

SEATTLE and VANCOUVER, British Columbia, March 7, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will be presenting at the Barclays 27th Annual Global Healthcare…

SEATTLE and VANCOUVER, British Columbia, February 11, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Rick Stewart, Chief Executive Officer of Achieve, will be presenting today at the virtual Oppenheimer 35th…

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial. Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025. SEATTLE and VANCOUVER, British Columbia, February 10, 2025 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation…

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia – January 10, 2025 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan…

Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission.  ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified.  Planned Cytisinicline NDA Submission on Target for Q2 2025. SEATTLE and VANCOUVER, British Columbia – January 7, 2025 Achieve Life…